Patient-specific modeling enables specific activity optimization to maximize tumor absorbed dose in transarterial radioembolization
In brief
A 14-patient model identified individualized settings to maximize tumor radiation dose
In simulations based on 14 patients with liver cancer, MIDOS identified patient-specific yttrium-90 settings that maximized modeled tumor dose while minimizing dose to normal liver. Synthetic images closely matched patient scans, with activity errors below 2%, but the best settings varied substantially between patients. The study supports feasibility, not improved outcomes in patients; clinical testing is still needed.
- Journal
- EJNMMI physics (Q1)
- Published
- 13 August 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Carlos Huesa-Berral, Robert J Dawson, Hamid Sabet, Macarena Rodríguez-Fraile, Raneem Atta, Harald Paganetti, et al.
- PMID
- 43009669
- DOI
- 10.1186/s40658-026-00921-0
Why clinicians should know about it
- Picked for Medical Physics (top studies of the week, 15 November 2026): Patient-specific SPECT-based activity optimization and absorbed-dose modeling
Abstract
BACKGROUND: Transarterial radioembolization (TARE) is evolving from palliative to curative in the management of hepatocellular carcinoma (HCC). Alongside, there is a growing need to develop personalized and predictive dosimetry strategies to maximize the therapeutic effect. The objective of this study was to evaluate the feasibility of a novel framework, MIDOS, to design patient-specific optimal TARE plans. METHODS: A retrospective cohort of fourteen TARE patients with solitary HCC who had [99mTc]Tc-MAA SPECT-CT was analyzed, including segmental and lobar administrations. For each patient, tumor and perfused area segmentations were included in a liver vasculature model. In our simulations, microspheres were stochastically assigned in cluster patterns to tumor or normal liver tissue, with probabilities proportional to flow and modulated by tumor and normal liver uptake models. Simulation results were employed to generate synthetic [99mTc]Tc-MAA SPECT images that were compared with patient images using the relative activity errors in tumor and normal tissue, tumor-to-normal ratio (TNR), and gamma analysis (10%/10 mm) of normal tissue distribution. Virtual 90Y treatment plans were generated using the prescribed activity across a range of specific activities (40-4000 Bq/bead), from which personalized treatment planning curves for TNR and tumor and normal liver mean absorbed dose were derived. RESULTS: Synthetic [99mTc]Tc-MAA SPECT images presented relative errors below 2% for overall tumor activity, normal liver activity, and TNR. Pass rates of 10%/10 mm for normal tissue distribution were above 90% in all patients. Treatment planning curves revealed patient- and scenario-specific optima in TNR, corresponding to maximal tumor mean dose and minimal normal liver mean dose, with substantial inter-patient variability in dose sensitivity to specific activity. CONCLUSION: This study shows the feasibility of MIDOS as a framework for quantitative treatment optimization in TARE under different clinical scenarios. This allows systematic optimization of treatment planning curves that maximize TNR and tumor mean dose as a function of the 90Y specific activity.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.